Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Among-Us study
NCT04730648Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Open-label trial in acute coronary syndrome (ACS) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Cardiovascular prognosis at 52 weeks. Status: unknown.
02
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04730648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730648.